Transformation Capital, the largest dedicated digital health venture and growth equity firm, has announced the final close of Transformation Capital Fund IV at its $850 million hard cap. The fund exceeded its target in an oversubscribed raise completed this summer. The announcement underscores the firm's continuing influence in technology and artificial intelligence investments across the U.S. healthcare sector.
Fund Details and Investor Demand
Fund IV attracted continued commitments from existing limited partners and a wave of new institutional investors joining the firm for the first time. The oversubscribed close raised Transformation Capital's total assets under management to more than $2.5 billion across four funds. The firm has already begun deploying Fund IV capital into new partner companies.
A Strategy Aligned With Healthcare's Evolution
Since 2009, U.S. healthcare has moved through successive waves of change, including electronic medical records, value-based payment models, telehealth adoption, and the rapid rise of artificial intelligence. Transformation Capital has invested behind each wave and completed eight new AI-focused investments in the past year alone. Fund IV will continue backing commercial-stage companies that use technology and AI to make healthcare more efficient, accessible, and accountable.
The AI Opportunity in Healthcare
Healthcare generates roughly 30 percent of the world's data, yet the industry meaningfully uses only about 3 percent of it, according to the firm's managing partners. That gap is where artificial intelligence is having its biggest impact, attacking more than $1 trillion in waste and inefficiency embedded in the system. Transformation Capital sees this as a defining investment opportunity for Fund IV and its partner companies.
Leadership With Operational and Clinical Depth
The firm is led by three managing partners whose backgrounds span entrepreneurship, medicine, and institutional investing. Todd Cozzens built and sold two healthcare companies, Jared Kesselheim is a Harvard-trained physician and former partner at Bain Capital Ventures, and Mike Dixon spent a decade as a general partner at Sequoia. The broader investment team includes professionals with experience from Goldman Sachs, Deutsche Bank, Bain and Company, and Evercore.
Executive Perspectives on the Fundraise
Jessica Pellegrini, Head of Capital Formation, said the demand for Fund IV is a strong endorsement of the firm's strategy at a pivotal moment for healthcare innovation. She emphasized that continued support from existing partners and new institutional demand was especially meaningful in a difficult fundraising environment. In a joint statement, the managing partners noted that artificial intelligence is the single largest market driver they have seen in nearly two decades of healthcare investing.
Founder Support and Sector Network
Transformation Capital has built a reputation among digital health founders for providing more than capital. The firm opens doors through strategic introductions across health plans, hospital systems, self-insured employers, and biopharma companies. Its team also helps management teams recruit executive talent and works alongside them on the operational challenges of scaling a business.
About Transformation Capital
Founded in 2016, Transformation Capital invests exclusively in commercial-stage companies transforming the delivery, cost, and quality of healthcare. The firm manages more than $2.5 billion in assets and has invested in over 50 digital health and AI-driven partner companies, including Datavant, Sword Health, Grow Therapy, SmarterDx, and Parachute Health. It is based in Boston and San Francisco.
The final close of Fund IV positions Transformation Capital to deepen its role in the next phase of AI-driven healthcare innovation. With fresh capital, a strengthened institutional investor base, and a sector-focused network, the firm is well placed to support founders tackling inefficiency and rising costs. The milestone also signals resilient investor confidence in digital health despite broader fundraising headwinds.